Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.63 |
| ▸ | HTR1A | P08908 | 1/20 | 0.56 |
| ▸ | PARP1 | P09874 | 1/20 | 0.53 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14601668 | 0.95 | SIGMAR1 (0.60) | SIGMAR1HTR1AKCNA3 | |
| SCHEMBL29363627 | 0.89 | SIGMAR1 (0.60) | SIGMAR1HTR1AKCNA3 | |
| SCHEMBL10254250 | 0.85 | SIGMAR1 (0.52) | SIGMAR1 | |
| SCHEMBL7297566 | 0.84 | SIGMAR1 (0.63) | SIGMAR1HTR1APARP1KCNA3 | |
| SCHEMBL5544346 | 0.84 | SIGMAR1 (0.63) | SIGMAR1HTR1APARP1KCNA3 | |
| SCHEMBL5847112 | 0.84 | SIGMAR1 (0.59) | SIGMAR1HTR1APARP1 | |
| Hydrochloric Acid SCHEMBL7299927 | 0.83 | SIGMAR1 (0.61) | SIGMAR1HTR1APARP1KCNA3 | |
| SCHEMBL5846286 | 0.83 | SIGMAR1 (0.61) | SIGMAR1HTR1APARP1 | |
| SCHEMBL5539537 | 0.83 | SIGMAR1 (0.61) | SIGMAR1HTR1APARP1KCNA3 | |
| SCHEMBL9726237 | 0.83 | SIGMAR1 (0.60) | SIGMAR1HTR1AKCNA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6392051-B2 | OXIDIZING A 4-PHENYL-N-ACYLDIHYDROPYRIDINE | CLARIANT GMBH (DE) | 2002-05-21 | — | — | US | claimed |
| US-20010021778-A1 | Process for preparing 4-(4'-carboxyphenyl)pyridine | CLARIANT GMBH | 2001-09-13 | — | — | US | claimed |
| EP-1125926-A1 | Process for the preparation of 4-(4'-carboxyphenyl)pyridine | Clariant GmbH (DE) | 2001-08-22 | — | — | EP | claimed |
| WO-2012028578-A1 | SUBSTITUTED FUSED PYRIMIDINONES AND DIHYDROPYRIMIDINONES | BAYER CROPSCIENCE AG (DE) | 2012-03-08 | — | — | WO | disclosed |
| US-20090149417-A1 | Methods and compositions for the treatment of cancer using benzopyrone-type PARP inhibitors | BIPAR SCIENCES, INC. | 2009-06-11 | — | — | US | disclosed |
| CN-101255170-A | 2,3-dihydroimidazo[2,1-b]oxazole compound | OTSUKA PHARMA CO LTD (JP) | 2008-09-03 | — | — | CN | disclosed |
| CN-101172981-A | 2,3-dihydroimidazo[2,1-b]oxazole compound | OTSUKA PHARMA CO LTD (JP) | 2008-05-07 | — | — | CN | disclosed |
| US-20080076778-A1 | METHODS FOR DESIGNING PARP INHIBITORS AND USES THEREOF | BIPAR SCIENCES, INC. (US) | 2008-03-27 | — | — | US | disclosed |
| CN-100366624-C | 2, 3-dihydro-6-nitroimidazo [2,1-b ] * azole compounds | OTSUKA PHARMA CO LTD (JP) | 2008-02-06 | — | — | CN | disclosed |
| CN-1705670-A | 2, 3-dihydro-6-nitroimidazo [2, 1-b ] oxazole compounds | OTSUKA PHARMA CO LTD (JP) | 2005-12-07 | — | — | CN | disclosed |
| US-6392051-B2 | OXIDIZING A 4-PHENYL-N-ACYLDIHYDROPYRIDINE | CLARIANT GMBH (DE) | 2002-05-21 | — | — | US | disclosed |
| US-6392051-B2 | OXIDIZING A 4-PHENYL-N-ACYLDIHYDROPYRIDINE | CLARIANT GMBH (DE) | 2002-05-21 | — | — | US | disclosed |
| JP-2001278861-A | METHOD FOR PRODUCING 4-(4'-CARBOXYPHENYL)PYRIDINE | CLARIANT GMBH | 2001-10-10 | — | — | JP | disclosed |
| US-20010021778-A1 | Process for preparing 4-(4'-carboxyphenyl)pyridine | CLARIANT GMBH | 2001-09-13 | — | — | US | disclosed |
| US-20010021778-A1 | Process for preparing 4-(4'-carboxyphenyl)pyridine | CLARIANT GMBH | 2001-09-13 | — | — | US | disclosed |
| EP-1125926-A1 | Process for the preparation of 4-(4'-carboxyphenyl)pyridine | Clariant GmbH (DE) | 2001-08-22 | — | — | EP | disclosed |
| EP-1125926-A1 | Process for the preparation of 4-(4'-carboxyphenyl)pyridine | Clariant GmbH (DE) | 2001-08-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010021778-A1 | Process for preparing 4-(4'-carboxyphenyl)pyridine | NOX4, CBR1, CBR3 | SIGMAR1 934/4885HTR1A 2247/4885PARP1 1526/4885 |
| US-20090149417-A1 | Methods and compositions for the treatment of cancer using benzopyrone-type PARP inhibitors | PARP1, PARP2, PARP3 | SIGMAR1 4587/4885HTR1A 2229/4885PARP1 1/4885 |
| US-20080076778-A1 | METHODS FOR DESIGNING PARP INHIBITORS AND USES THEREOF | PARP3, PARP1, PARP15 | SIGMAR1 4571/4885HTR1A 1869/4885PARP1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.